Detalles de la búsqueda
1.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Blood
; 128(4): 497-503, 2016 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27226434
2.
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Eur J Haematol
; 99(3): 199-206, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28504846
3.
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Haematologica
; 101(7): 872-8, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27081177
4.
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Br J Haematol
; 168(6): 820-3, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403264
5.
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Haematologica
; 100(10): 1327-33, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26250580
6.
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Haematologica
; 100(10): 1334-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160879
7.
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.
Cancer
; 120(3): 335-43, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24127346
8.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(11): 1055-1066, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007748
9.
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
Invest New Drugs
; 30(5): 1958-61, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22002018
10.
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Gynecol Oncol
; 125(1): 42-7, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22112608
11.
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Haematologica
; 100(2): e63-7, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425684
12.
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Clin Pharmacokinet
; 59(2): 217-227, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31332669
13.
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Leuk Lymphoma
; 60(2): 462-470, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30068263
14.
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.
Clin Pharmacol
; 9: 133-145, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29184451
15.
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Leuk Lymphoma
; 57(12): 2839-2847, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27173785
16.
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Leuk Lymphoma
; 57(12): 2833-2838, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27267105
17.
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Clin Lymphoma Myeloma Leuk
; 15(9): 519-30, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149712
18.
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
J Clin Oncol
; 28(2): 207-14, 2010 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19949018
19.
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
J Thorac Oncol
; 5(7): 1054-9, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20593550
Resultados
1 -
19
de 19
1
Próxima >
>>